Exome Sequencing Provides Diagnostic Assay for Intellectual Disability
|
By LabMedica International staff writers Posted on 22 Nov 2012 |
A molecular based diagnostic assay has been used determine whether one or more genetic mutations explain a patient's intellectual disability.
Exome sequencing, which deciphers over 21,000 protein-coding genes and not the entire human genome, can be used as a diagnostic assay to determine the genetic mutations that may elucidate why some patients suffer from significant limitations both in intellectual functioning and in adaptive behavior.
A team of scientists at Radboud University (Nijmegen, The Netherlands) performed exome sequencing of 100 patients with unexplained cognitive impairment, and uncovered 79 genes with unique de novo mutations. These de novo mutations were present in the DNA of the patients but not in that of their parents whose exomes also were sequenced.
The diagnostic interpretation revealed that 16 of the 100 mutations were causative, or pathogenic. Ten of these mutations occurred in genes already known to be involved in intellectual disability, and three X-linked maternally inherited mutations were identified. In addition, de novo mutations were uncovered in three novel candidate genes, which after follow-up were found to be more frequently mutated in patients with intellectual disability. Furthermore, disruptive de novo mutations were identified in 19 additional genes with a functional link to intellectual disability. Because 19 genes were found in only a single patient, a conclusive diagnosis based on these findings could not be made.
Joseph de Ligt, MSc, bioinformatician and PhD student in human genetics, said, “The child with a cognitive disability is often an isolated case without family history of the condition, and that intellectual disability occurs in about 1% of the population. All de novo as well as X-linked mutations identified in this study were interpreted in the context of the clinical diagnosis.” The results of this study were presented on November 8, 2012, at the American Society of Human Genetics meeting, held in San Francisco, (CA, USA).
Related Links:
Radboud University
Exome sequencing, which deciphers over 21,000 protein-coding genes and not the entire human genome, can be used as a diagnostic assay to determine the genetic mutations that may elucidate why some patients suffer from significant limitations both in intellectual functioning and in adaptive behavior.
A team of scientists at Radboud University (Nijmegen, The Netherlands) performed exome sequencing of 100 patients with unexplained cognitive impairment, and uncovered 79 genes with unique de novo mutations. These de novo mutations were present in the DNA of the patients but not in that of their parents whose exomes also were sequenced.
The diagnostic interpretation revealed that 16 of the 100 mutations were causative, or pathogenic. Ten of these mutations occurred in genes already known to be involved in intellectual disability, and three X-linked maternally inherited mutations were identified. In addition, de novo mutations were uncovered in three novel candidate genes, which after follow-up were found to be more frequently mutated in patients with intellectual disability. Furthermore, disruptive de novo mutations were identified in 19 additional genes with a functional link to intellectual disability. Because 19 genes were found in only a single patient, a conclusive diagnosis based on these findings could not be made.
Joseph de Ligt, MSc, bioinformatician and PhD student in human genetics, said, “The child with a cognitive disability is often an isolated case without family history of the condition, and that intellectual disability occurs in about 1% of the population. All de novo as well as X-linked mutations identified in this study were interpreted in the context of the clinical diagnosis.” The results of this study were presented on November 8, 2012, at the American Society of Human Genetics meeting, held in San Francisco, (CA, USA).
Related Links:
Radboud University
Latest Molecular Diagnostics News
- ctDNA Blood Test Could Help Guide Radiotherapy in Patients with Limited Metastases
- FDA-Approved MRD Blood Test Guides Adjuvant Bladder Cancer Therapy
- Tumor Genomic Profiling Identifies High-Risk Gallbladder Cancer
- Novel Algorithm Improves Detection of B-ALL Gene Fusions
- Rapid Multiplex PCR Test Detects 11 Gastrointestinal Pathogens from Single Sample
- Sensitive Protein Marker Aids Diagnosis of Small Cell Prostate Cancer
- Genome Sequencing Uncovers Hidden Genetic Risks in Healthy Adults
- Gene Panel Shows Promise for Predicting Chemotherapy Response in TNBC
- Realistic Mock Samples Aim to Speed Cervical Cancer Test Development
- Blood-Based “Ageing Clock” Helps Predict Dementia Risk and Earlier Onset
- Molecular Marker Identifies Hormone Therapy Resistance Pathway in Prostate Cancer
- Blood Test Refines Biopsy Decisions in Prostate Cancer
- Digital Aging Twin Quantifies Biological Aging Across Multiple Organ Systems
- Emerging Biomarkers Advance Early Detection of MASLD and Liver Cancer Risk
- Urine Test Beats MRI in Identifying Prostate Cancer Upgrading During Active Surveillance
- Finger-Prick Blood Test Aids Early Tuberculosis Detection and Risk Stratification
Channels
Clinical Chemistry
view channel
Urine-Based Nanosensor Tracks Lung Cancer and Fibrosis Noninvasively
Lung cancer remains difficult to monitor for early progression and treatment resistance, while pulmonary fibrosis continues to pose major challenges for early diagnosis. Clinicians need repeatable, noninvasive... Read more
Blood-Based Alzheimer’s Test Gains CE Mark for Amyloid Pathology Detection
Alzheimer’s disease is the most common cause of dementia, yet confirmatory testing remains invasive and hard to access. Diagnosis currently takes an average of 3.5 years, and about 75% of people with dementia... Read moreHematology
view channel
Stem Cell Biomarkers May Guide Precision Treatment in Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is an aggressive blood cancer that most often affects older adults and still carries a poor prognosis despite therapeutic advances. Venetoclax-based regimens have improved... Read more
Advanced CBC-Derived Indices Integrated into Hematology Platforms
Diatron, a STRATEC brand, has introduced six advanced hematological indices on its Aquila, Aquarius 3, and Abacus 5 hematology analyzers. The new Research Use Only (RUO) indices include Neutrophil-to-Lymphocyte... Read moreImmunology
view channel
Routine TB Screening Test May Reveal Immune Aging and Mortality Risk
Immune aging is associated with weaker responses to vaccination, greater risks of infection, and higher levels of inflammation. Leveraging routinely ordered laboratory tests to quantify that responsiveness... Read more
Biomarkers and Molecular Testing Advance Precision Allergy Care
Allergic diseases often present with similar symptoms but can be driven by distinct biological mechanisms, making standardized care inefficient for many patients. Historically, individuals with pollen... Read moreMicrobiology
view channel
Study Finds Hidden Mpox Infections May Drive Ongoing Spread
Mpox continues to circulate despite vaccination, and many cases show no known link to a symptomatic partner. The role of people without symptoms has remained uncertain, limiting clarity on how transmission persists.... Read more
Large-Scale Genomic Surveillance Tracks Resistant Bacteria Across European Hospitals
Antimicrobial resistance (AMR) poses a growing threat to patient safety, with carbapenem-resistant Enterobacterales causing difficult-to-treat infections and leaving clinicians with limited therapeutic options.... Read more
Molecular Urine and Stool Tests Do Not Improve Early TB Treatment in Hospitalized HIV Patients
Tuberculosis is the leading cause of death among people living with HIV, and diagnosis in hospital settings remains difficult. Symptoms are often non-specific, disease can be extrapulmonary, and many patients... Read morePathology
view channel
Rapid AI Tool Predicts Cancer Spatial Gene Expression from Pathology Images
Gene expression profiling can inform tumor biology and treatment selection, but spatial assays remain costly and time-consuming. Results can take weeks and cost thousands of dollars, limiting large-scale... Read more
AI Pathology Test Receives FDA Breakthrough for Bladder Cancer Risk Stratification
Non–muscle invasive bladder cancer has highly variable outcomes, complicating surveillance and treatment planning. Risk assessment typically relies on stage, grade, and tumor size, leaving uncertainty... Read moreTechnology
view channel
Point-of-Care Testing Enhances Health Literacy and Self-Management in Chronic Disease
Limited access to general practitioners and pathology services can delay diagnosis and monitoring for people in regional and remote communities. Rapid, on-the-spot testing can shorten turnaround times... Read more
Fully Automated Sample-to-Insight Workflow Advances Latent TB Testing
Latent tuberculosis remains a substantial testing workload for clinical laboratories as screening programs expand. Despite this growth, only about 40% of testing has shifted from traditional skin tests... Read moreIndustry
view channel
AI-Powered Multi-Functional Analyzer Wins German Innovation Award
Hematology services are increasingly delivered across distributed care settings, where limited staffing and complex workflows can extend turnaround times. Advanced morphology review still often depends... Read more




.jpg)



